FDA has approved Scholar Rock’s myostatin-inhibition therapy Isembyld (for adults and children 2 years and older) for spinal muscular atrophy patients who are already receiving SMN2-targeting treatment. The decision centers on a late-stage trial in which Isembyld, when added to an SMN2 drug, improved motor outcomes after one year versus decline in a placebo group. The approval marks a milestone for the SMA community because it targets muscle loss rather than SMN protein production. That distinction is expected to influence how combination regimens are constructed for patients across age bands and clinical risk categories. Industry implications include renewed momentum for non-SMN approaches in SMA and a clearer regulatory pathway for combination strategies that build on existing SMN2 therapies.